7,000 AbbVie Inc. $ABBV Shares Purchased by Sivik Global Healthcare LLC

Key Points

• Sivik Global Healthcare increased its AbbVie stake by 46.7% in the third quarter, purchasing 7,000 shares to bring its total to 22,000 shares valued at approximately $5.8 million. Institutional investors collectively own 70.23% of AbbVie.
• AbbVie’s growth outlook is supported by durable demand for SKYRIZI and RINVOQ, along with potential pipeline opportunities in oncology and obesity, though competition and concerns about replacing Humira revenue remain.
• Shares recently traded at $276.35, near their 52-week high, while analysts maintain a “Moderate Buy” consensus with an average $277.18 price target. AbbVie also declared a quarterly dividend of $1.73 per share, representing a 2.5% annualized yield.

Sivik Global Healthcare LLC lifted its stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 46.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 22,000 shares of the company's stock after purchasing an additional 7,000 shares during the period. AbbVie accounts for 3.6% of Sivik Global Healthcare LLC's investment portfolio, making the stock its 5th biggest holding. Sivik Global Healthcare LLC's holdings in AbbVie were worth $5,755,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently modified their holdings of ABBV. Corient Private Wealth LP purchased a new stake in AbbVie in the second quarter worth $559,736,000. Legal & General Group Plc bought a new stake in shares of AbbVie in the second quarter valued at $2,905,952,000. Jupiter Topco LLC purchased a new position in shares of AbbVie during the 2nd quarter valued at $1,560,354,000. Diamant Asset Management Inc. lifted its position in shares of AbbVie by 21,649.0% during the 1st quarter. Diamant Asset Management Inc. now owns 3,671,231 shares of the company's stock valued at $798,456,000 after buying an additional 3,654,351 shares during the last quarter. Finally, Canada Pension Plan Investment Board bought a new position in shares of AbbVie during the 2nd quarter worth $817,473,000. Institutional investors own 70.23% of the company's stock.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Fresh clinical and regulatory developments are strengthening AbbVie’s growth narrative. Phase 3 data for SKYRIZI and RINVOQ in Crohn’s disease, along with FDA Breakthrough Therapy Designations for temab-A in colorectal and lung cancer, could expand the company’s long-term commercial opportunities. Early obesity data also add potential upside to the pipeline. AbbVie Could Be 44% Below Fair Value on Fresh Pipeline Wins
• Positive Sentiment: Long-term data presented at ACG 2026 continue to support the durability and growth prospects of SKYRIZI and RINVOQ. Analysts expect the two therapies to offset part of Humira’s revenue erosion and drive third-quarter top-line growth. AbbVie Highlights Long-Term SKYRIZI and RINVOQ Data
• Positive Sentiment: Royal Bank of Canada reaffirmed its Outperform rating and assigned a $280 price target, indicating continued confidence in AbbVie’s earnings outlook despite limited near-term upside at current levels.
• Neutral Sentiment: Recent coverage highlights AbbVie as an attractive income stock after market weakness pushed its dividend yield higher. That may support defensive and income-oriented demand, though the yield increase also reflects recent selling pressure. High-Yield Dividend Stocks
• Negative Sentiment: At a lofty valuation following a substantial rally, investors may be taking profits while assessing whether SKYRIZI and RINVOQ can fully replace Humira sales. Rising competition in immunology and the stock’s limited analyst-implied upside are additional near-term headwinds. Will SKYRIZI and RINVOQ Drive AbbVie’s Top-Line Growth?

AbbVie Price Performance

Shares of NYSE:ABBV traded down $4.77 on Tuesday, hitting $276.35. The company's stock had a trading volume of 2,013,791 shares, compared to its average volume of 6,391,498. The company has a market capitalization of $488.26 billion, a PE ratio of 78.08, a PEG ratio of 1.26 and a beta of 0.24. The company has a 50-day simple moving average of $259.79 and a 200 day simple moving average of $237.39. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $283.43.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to analysts' expectations of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business's quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter last year, the company posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities research analysts expect that AbbVie Inc. will post 13.94 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.5%. AbbVie's dividend payout ratio is presently 195.48%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on ABBV shares. UBS Group lifted their price objective on AbbVie from $260.00 to $275.00 and gave the stock a "neutral" rating in a report on Tuesday, October 6th. Rothschild & Co Redburn upped their price objective on shares of AbbVie from $284.00 to $285.00 and gave the company a "buy" rating in a report on Tuesday, August 4th. Bank of America reaffirmed a "buy" rating on shares of AbbVie in a report on Tuesday, September 8th. Citigroup increased their target price on shares of AbbVie from $230.00 to $260.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 15th. Finally, HSBC lifted their target price on shares of AbbVie from $300.00 to $315.00 and gave the stock a "buy" rating in a research note on Thursday, September 10th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $277.18.

Insiders Place Their Bets

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the company's stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.06% of the company's stock.

AbbVie Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women's health.

The company's products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.